Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Advertising (290)
- COVID-19 (164)
- Safety monitoring and information (114)
- Compliance and enforcement (89)
- Legislation (78)
- Manufacturing (60)
- Vaping hub (57)
- Labelling and packaging (42)
- Import and export (37)
- Medicinal cannabis hub (27)
- Scheduling (national classification system) (27)
- Sunscreens (20)
- Weight loss products (18)
- Shortages and supply disruptions (11)
- Committees and advisory bodies (9)
- Cosmetics (6)
- Unique Device Identification (UDI) hub (5)
- Clinical trials (3)
- Fees and payments (2)
- Prescription opioids hub (2)
- Urogynaecological (transvaginal) surgical mesh hub (2)
- Breast implant hub (1)
Search
1286 result(s) found, displaying 1 to 25
-
Media releasesTGA has issued an infringement notice, to the value of $19,800, to Cellife Health Care Pty Ltd (Cellife) for the alleged supply of a listed medicine that did not comply with an applicable standard, in contravention of the Therapeutic Goods Act 1989
-
News articlesFollowing a public consultation process between 24 November 2025 – 10 February 2026, the TGA has adopted 23 international scientific guidelines
-
Safety updatesProduct warnings across the glucagon-like-peptide-1 receptor agonist (GLP-1 RA) class of medicines have been updated due to the potential for these products to cause a rare, but severe, form of eye disorder.
-
Regulatory decision noticesWe have added our recent decisions to the list of Australian manufacturers licensed by the TGA.
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.
-
Media releasesUnapproved peptide products are being advertised as delivering fast health results, but they can pose serious health risks to consumers.
-
Media releasesNew regulations are now in place across Australia to protect public health, by restricting access to nicotine pouches.
-
News articlesTGA has released a new information page relating to the availability of s 9D(1) of the Act to correct information in the ARTG about listed medicines.
-
Media releasesThe TGA, in partnership with NT Health, Northern Territory Police Force and the Northern Territory Department of Trade, Business and Asian Relations, conducted a targeted multi-agency enforcement operation across three premises in Darwin.
-
Media releasesWe have issued 5 infringement notices totalling $99,000 to Acacia Pharmacy Pty Ltd for the alleged unlawful importation of unapproved melatonin products, in contravention of the Therapeutic Goods Act 1989.
-
Media releasesIn March 2026, the Therapeutic Goods Administration (TGA) issued 3 infringement notices totalling $59,400 to Queensland-based company Canngea Pty Ltd.
-
News articlesWe've launched a series of interactive e-learning modules designed to help stakeholders understand their regulatory obligations.
-
Safety updatesCases of liver injury associated with herbal preparations containing Withania somnifera, commonly known as Ashwagandha, continue to be reported both in Australia and internationally.
-
Media releasesWe have issued 3 infringement notices totalling $11,880 to a nurse for the alleged unlawful importation of unapproved cosmetic injectables, which is illegal under the Therapeutic Goods Act 1989 (the Act).
-
News articlesFrom 1 July 2026, some medical devices supplied in Australia must meet Unique Device Identification (UDI) requirements.
-
News articlesWe've updated the Listed Medicine Compliance Reports database with the results of compliance reviews covering 13 listed medicines.
-
Media releasesAustralia’s health leaders are increasingly concerned about the growing availability, promotion and use of unapproved peptide products in Australia.
-
Media releasesWe have published new guidance on advertising restrictions for prescription medicines. This is to help individuals and businesses comply with Australia’s regulatory requirements.
-
News articlesListed medicine ingredients and requirements for their use have been updated in the Therapeutic Goods (Permissible Ingredients) Determination (No. 2) 2026 .
-
Media releasesWe have issued 5 infringement notices totalling $19,800 to a health practitioner and an individual for the alleged unlawful importation of unapproved cosmetic injectables.
-
Safety updatesInformation for health professionals about medicines with safety related updates to their Product Information.
-
Regulatory decision noticesSix monthly report – supply of unapproved therapeutic goods by a sponsor.
-
Media releasesWe have expanded our priority focus areas to include unapproved peptide products, following increased detection of unlawful importation, supply and advertising, posing potential risks to consumer safety.
-
Safety updatesWe have identified reports of FluMist being administered in error to children under 2 years of age.
-
BlogMedicinal cannabis prescribing in Australia has increased significantly in recent years. However, many patients are unaware that most medicinal cannabis products are unapproved goods. As a prescriber, you play a critical role in ensuring patients are informed, protected and supported when these products are being considered for their clinical situation.